These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33084176)

  • 1. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis.
    O'Hara S; Castro FA; Black J; Chaplin S; Ruiz L; Hampton RJ; Sima CS; O'Hara J
    Haemophilia; 2021 Jan; 27(1):113-119. PubMed ID: 33084176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Humanistic Burden of Non-inhibitor Haemophilia A in Five European Countries: Insights from the CHESS II Study.
    Ferri Grazzi E; Becker T; Brandt S; Duport G; Garcia Diego DA; Lupi A; McKeown W; Morgan D; Camp C; Hawes C; Blenkiron T; O'Hara J; Burke T
    Adv Ther; 2024 Oct; 41(10):3888-3904. PubMed ID: 39153051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A.
    O'Hara J; Noone D; Jain M; Pedra G; Landis S; Hawes C; Burke T; Camp C
    Haemophilia; 2021 Nov; 27(6):938-946. PubMed ID: 34273215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe.
    Burke T; Asghar S; O'Hara J; Chuang M; Sawyer EK; Li N
    Orphanet J Rare Dis; 2021 Dec; 16(1):521. PubMed ID: 34930388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the relationship between condition severity and health-related quality of life in people with haemophilia A across Europe: a multivariable analysis of data from the CHESS II study.
    Ferri Grazzi E; Hawes C; Camp C; Hinds D; O'Hara J; Burke T
    Health Qual Life Outcomes; 2024 Jul; 22(1):58. PubMed ID: 39075533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.
    Crivianu-Gaita V; Rivard GE; Carcao M; Teitel J; St-Louis J; Blanchette V; Pullenayegum E; Abad A; Feldman BM
    Haemophilia; 2016 Sep; 22(5):e401-5. PubMed ID: 27481574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia.
    den Uijl IE; Fischer K; Van Der Bom JG; Grobbee DE; Rosendaal FR; Plug I
    Haemophilia; 2009 Jan; 15(1):83-90. PubMed ID: 18713246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis for severe haemophilia: clinical and economical issues.
    Fischer K; Van Den Berg M
    Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A; Oldenburg J; Lissitchkov T; Knaub S; Bichler J; Manco-Johnson MJ
    Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world resource use and costs of haemophilia A-related bleeding.
    Shrestha A; Eldar-Lissai A; Hou N; Lakdawalla DN; Batt K
    Haemophilia; 2017 Jul; 23(4):e267-e275. PubMed ID: 28574162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
    Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
    Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients.
    Royal S; Schramm W; Berntorp E; Giangrande P; Gringeri A; Ludlam C; Kroner B; Szucs T;
    Haemophilia; 2002 Jan; 8(1):44-50. PubMed ID: 11886464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The overall effectiveness of prophylaxis in severe haemophilia.
    Panicker J; Warrier I; Thomas R; Lusher JM
    Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients.
    Ingerslev J; Lethagen S; Hvitfeldt Poulsen L; Sørensen B; Lopatina E; Tentsova I; Yastrubinetskaya O; Plyushch OP
    Haemophilia; 2014 Jan; 20(1):58-64. PubMed ID: 24354479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life.
    O'Hara J; Walsh S; Camp C; Mazza G; Carroll L; Hoxer C; Wilkinson L
    Health Qual Life Outcomes; 2018 May; 16(1):84. PubMed ID: 29720192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study.
    Manco-Johnson MJ; Sanders J; Ewing N; Rodriguez N; Tarantino M; Humphries T;
    Haemophilia; 2013 Sep; 19(5):727-35. PubMed ID: 23750875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.